Abstract
Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 357-364 |
| Number of pages | 8 |
| Journal | Surgery |
| Volume | 134 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. / Stiles, Brendon M.; Bhargava, Amit; Adusumilli, Prasad S.; Stanziale, Stephen F.; Kim, Teresa H.; Rusch, Valerie W.; Fong, Yuman.
In: Surgery, Vol. 134, No. 2, 01.08.2003, p. 357-364.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer
AU - Stiles, Brendon M.
AU - Bhargava, Amit
AU - Adusumilli, Prasad S.
AU - Stanziale, Stephen F.
AU - Kim, Teresa H.
AU - Rusch, Valerie W.
AU - Fong, Yuman
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.
AB - Background. The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. Methods. BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. Results. NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. Conclusion. NW1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy.
UR - http://www.scopus.com/inward/record.url?scp=0041326572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041326572&partnerID=8YFLogxK
U2 - 10.1067/msy.2003.244
DO - 10.1067/msy.2003.244
M3 - Article
C2 - 12947341
AN - SCOPUS:0041326572
VL - 134
SP - 357
EP - 364
JO - Surgery (United States)
JF - Surgery (United States)
SN - 0039-6060
IS - 2
ER -